GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 221 ( ` in lakhs) As at March 31, 2021 (j) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 1,57.35 GlaxoSmithKline Export Limited, U.K. 10,63.89 GlaxoSmithKline Research & Development Ltd., U.K. 15.70 GlaxoSmithKline Services Unlimited, U.K. 66.46 Glaxo Operations UK Limited, U.K. 1,32.05 GSK India Global Services Private Limited 2,83.84 ( ` in lakhs) As at March 31, 2021 (k) Outstanding payables at the period end : GlaxoSmithKline Pte Limited, Singapore 46.17 GlaxoSmithKline Biologicals S.A., Belgium 75,78.57 GlaxoSmithKline Export Limited, U.K. 23,27.92 Stiefel India Private Limited, India 1,49.50 GlaxoSmithKline Services Unlimited, U.K. 32.50 GlaxoSmithKline Asia Private Limited, India 17,79.02 SmithKline Beecham Limited, U.K. 26.68 ( ` in lakhs) As at March 31, 2021 (l) Cross charges recoverable at the period end : GSK India Global Services Private Limited 4.82 ( ` in lakhs) As at March 31, 2020 (m) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 1,92.68 GlaxoSmithKline Consumer Healthcare Limited, India 1,41.80 GlaxoSmithKline Export Limited, U.K. 63.35 GlaxoSmithKline Research & Development Ltd., U.K. 21.34 GlaxoSmithKline Trading Services Limited, Ireland 13.15 GlaxoSmithKline Services Unlimited, U.K. 69.60 Glaxo Operations UK Limited, U.K. 1,97.21 GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka 30.10